LT-1001 / LTT Bio-Pharma, Sino Biopharm - LARVOL DELTA

PROSPER: a phase III trial of lecithinized superoxide dismutase to prevent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. (PubMed, ESMO Gastrointest Oncol) - "Compared with superoxide dismutase (SOD), lecithinized SOD (PC-SOD) exhibits much longer stability in plasma, thus reducing oxidative stress, which is a key mechanism of CIPN...The primary endpoint is the time to onset of grade ≥2 CIPN (Common Terminology Criteria for Adverse Events). Key secondary endpoints include the time to onset of grade ≥2 CIPN (Neurotoxicity Criteria of Debiopharm) and oxaliplatin allergy."

Clinical • Journal • P3 data • Allergy • Colorectal Adenocarcinoma • Colorectal Cancer • Immunology • Oncology • Pain • Solid Tumor

CMTNet: A hybrid CNN-Mamba-Transformer network for point cloud salient object detection. (PubMed, Neural Netw) - "Furthermore, a Mamba Guided Feature Fusion (MGFF) module is introduced to fuse hierarchical features and enhance long-range dependency modeling. Extensive experiments on the PCSOD dataset demonstrate our approach outperforms current state-of-the-art methods in both effectiveness and efficiency."

Journal

Preventive effect of PC-SOD on oxaliplatin-induced peripheral neuropathy in rats. (PubMed, BMC Neurosci) - No abstract available

Journal • Preclinical • Pain

Non-lethal heat shock unlocks SOD gene family diversity for enhanced bacterial resistance in Procambarus clarkii. (PubMed, Front Immunol) - "Significant correlations between PcSOD and ERS genes were observed in hemocytes under NLHS + V. parahaemolyticus treatment, supported by NLHS-induced Hsp70. These findings suggest a potential coordinated SOD-ERS response in P. clarkia, providing insights for aquaculture disease control strategies."

Journal

Learning global-view correlation for salient object detection in 3D point clouds. (PubMed, Neural Netw) - "GBCF establishes dense correlations between global space and channel descriptors, which are then leveraged to properly purify saliency representations. Experimental evaluations on the PCSOD benchmark demonstrate that our proposed method achieves state-of-the-art accuracy and significantly outperforms other compared methods."

Journal

Prophylactic administration of lecithinized superoxide dismutase for a murine model of oxaliplatin-induced myelosuppression. (PubMed, Front Pharmacol) - "Oxaliplatin, in combination with 5-fluorouracil and leucovorin, is a standard treatment for colorectal cancer and shows high efficacy. Furthermore, analysis of mouse-derived bone marrow cells revealed that PC-SOD suppressed oxaliplatin-induced cytotoxicity and ROS production in vitro. These results suggest that PC-SOD exerts an antioxidant effect and prevents oxaliplatin-induced myelosuppression, particularly in a murine model of leukopenia."

Journal • Preclinical • Colorectal Cancer • Hematological Disorders • Leukopenia • Oncology • Pain • Solid Tumor • CSF2 • IL4 • IL5 • IL6 • IL9

An Electron Paramagnetic Resonance Study of the Superoxide-Scavenging and Redox-Modulating Effects of Lecithinized Superoxide Dismutase in the Bloodstream. (PubMed, Molecules) - "The possible reason is the longer half-life of PC-SOD in the bloodstream, its better stability, and its slower clearance from the circulation due to the increased hydrophobicity of the enzyme and its interaction with plasma proteins. The data are discussed in the context of recent clinical trials showing that PC-SOD is a promising pharmaceutical product for adjuvant therapy of a variety of pathologies accompanied by inflammation, redox imbalance, and oxidative stress."

Journal • Inflammation

New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study. (ASCO 2024) - "The primary endpoint did not occur; however, the study group had a significantly greater number of cycles before DEB-NTC G2 PN. Notably, the study group also had a significantly greater number of cycles before HSR. These results show that PC-SOD may suppress HSR as well as PN, both of which limit administration of oxaliplatin."

Clinical • Colorectal Cancer • Dental Disorders • Gastrointestinal Cancer • Hematological Disorders • Immunology • Neutropenia • Oncology • Pain • Solid Tumor • Stomatitis

Novel pharmacological effects of lecithinized superoxide dismutase on ischemia/reperfusion injury in the kidneys of mice. (PubMed, Life Sci) - "These results suggest that PC-SOD inhibits AKI and the transition from AKI to CKD through the inhibition of ROS production. Therefore, we believe that PC-SOD may represent an effective therapeutic agent for I/R-induced renal injury."

Journal • Preclinical • Acute Kidney Injury • Chronic Kidney Disease • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Reperfusion Injury • IL6 • LCN2

Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19? (PubMed, Biomed Pharmacother) - "The lecitinized superoxide dismutase (PC-SOD) could represent a possibility because of bioaviability, safety, and its modulatory effect on the innate immune response in reducing the harmful consequences of oxidative stress. In this review we summarize the evidence on lecitinized superoxide dismutase in animal and human studies, to highlight the rationale for using the PC-SOD to treat COVID-19."

Journal • Review • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Postharvest Application of Acibenzolar-S-methyl Delays the Senescence of Pear Fruit by Regulating Reactive Oxygen Species and Fatty Acid Metabolism. (PubMed, J Agric Food Chem) - "Postharvest ASM dipping remarkably enhanced PcSOD, PcCAT, PcAPX, and PcDHAR expressions, and fatty acid synthetase activity in pears...ASM distinctly inhibited PcPLD, PcLOX, PcHPL, PcADH and PcAAT expressions in pears. The findings suggest that postharvest applying ASM could modulate ROS and fatty acid metabolism to delay senescence in pears."

Journal • CAT • GSR

MAGNUMPA: Magnesium Nebulization Utilization in Management of Pediatric Asthma (clinicaltrials.gov) - P2; N=818; Completed; Sponsor: The Hospital for Sick Children; Recruiting ➔ Completed; Trial completion date: Dec 2020 ➔ Nov 2019; Trial primary completion date: Dec 2020 ➔ Nov 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date

Pharmacokinetics and safety of PC-SOD, a lecithinized recombinant superoxide dismutase, in healthy Chinese subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. (PubMed, Int J Clin Pharmacol Ther) - "Single intravenous administrations of PC-SOD in doses up to 160 mg were well tolerated in healthy Chinese subjects. The prolonged half-life of PC-SOD was confirmed and independent of dose. Over the range of 20 - 160 mg, PC-SOD showed approximate dose proportionality. These findings suggest that it is worthwhile to investigate PC-SOD in clinical conditions characterized by a high radical overload."

Clinical • Journal • P1 data • PK/PD data

Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Beijing Tide Pharmaceutical Co., Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

MAGNUMPA: Magnesium Nebulization Utilization in Management of Pediatric Asthma (clinicaltrials.gov) - P2; N=816; Recruiting; Sponsor: The Hospital for Sick Children; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2017 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date

Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Beijing Tide Pharmaceutical Co., Ltd

Clinical • New P2 trial